Lieping Chen, MD, PhD
United Technologies Professor in Cancer Research
Professor of Immunobiology, Dermatology & Medicine
Director of Cancer Immunology
Yale University School of Medicine

Dr. Chen earned his medical degree from Fujian Medical School in China. After completion of clinical training in immunology and oncology in Fujian Union Hospital and Beijing Union Medical College, he earned PhD from Drexel University in Philadelphia and did a postdoctoral fellowship in the University of Washington in Seattle. He worked as a research scientist in Bristol-Myers Squibb-Seattle 1990 - 1997. He became Associate Professor of Immunology in Mayo Clinic and promoted to the rank of Professor in 2000. He was Professor of Oncology and Dermatology in Johns Hopkins School of Medicine from 2004. Dr. Chen joined Yale University since 2011. Lieping Chen studies cell surface molecules and their functions in the modulation of immune responses. His laboratory is the first to use costimulation to enhance tumor immunity (by transfection of B7-1 gene into tumor cells). This study establishes the principle for costimulation and immune checkpoint blockade for cancer therapy. Dr. Chen co-discovered the PD-1/PD-L1 pathway and elucidated the role of the PD-1/PD-L1 pathway in tumor site immune suppression. More importantly, he invented anti-PD-1/PD-L1 therapy for cancer. His laboratory also discovered or co-discovered multiple immune modulation pathways, their functions and application in human disease treatment including 4-1BB (CD137), B7-H2 (ICOSL), B7-H3, B7-H4, B7-H5/CD28H, PD-1H (VISTA) and LIGHT/HVEM. Dr. Chen's studies led to the development of anti-PD-1/PD-L1 therapy against broad spectrum of terminal stage human cancer (FDA approved drugs in 2014). In addition, agonist anti-4-1BB (CD137) antibodies (cancer), B7-H4Ig (rheumatoid arthritis) and anti-B7-H3 antibodies (cancer) are all in different stages of clinical development due to his laboratory discoveries. Dr. Chen has published more than 300 papers, review, book chapters and edited two books. He has received several awards and professional recognitions including United Technologies Endowed Chair in Cancer Research in Yale University (2013) and William B. Coley Award (2014). His work in discovery of the PD-1/PD-L1 pathway in cancer therapy was cited as the #1 breakthrough of the years by Science magazine (2013).



Zhijian (James) Chen, PhD
George MacGregor Distinguished Chair in Biomedical Sciences
Professor, Department of Molecular Biology
University of Texas Southwestern Medical Center
Investigator, Howard Hughes Medical Institute
Member of U.S. National Academy of Sciences

Dr. Zhijian 'James' Chen is an Investigator of the Howard Hughes Medical Institute and the George L. MacGregor Distinguished Chair in Biomedical Science at UT Southwestern Medical Center. He is also an elected fellow at the American Association for the Advancement of Science. Dr. Chen received his PhD degree from SUNY-Buffalo and continued a postdoctoral training at the Salk Institute. Before moving to

UT Southwestern, Dr. Chen worked at the ProScript Incorporation as a senior scientist. Dr. Chen's major research interest is to understand the function of ubiquitin-proteasome pathway, NF-kappaB and RIG-1 signaling pathways in innate immune response.



Chuan He, PhD
John T. Wilson Distinguished Service Professor
Director of the Institute for Biophysical Dynamics
University of Chicago
Investigator, Howard Hughes Medical Institute

Dr. He was born in P. R. China in 1972 and received his B.S. (1994) from the University of Science and Technology of China. He received his Ph. D. degree from Massachusetts Institute of Technology in chemistry in 2000 with Professor Stephen J. Lippard. After being trained as a Damon-Runyon postdoctoral fellow with Professor Gregory L. Verdine at Harvard University from 2000-2002, he joined the University of Chicago as an assistant professor, and was promoted to associate professor in 2008 and full professor in 2010. He was selected as an as an Investigator of the Howard Hughes Medical Institute in 2013. He is also a member of the Cancer Research Center at the University of Chicago. His research spans a broad range of epigenetics, chemical biology, biochemistry, molecular biology, cell biology, and genomics. His recent research concerns reversible RNA and DNA methylation in biological regulation. His laboratory discovered reversible RNA methylation as a fundamental new mechanism of gene expression at the post-transcriptional level in 2011.

Frank Hu, MD, PhD
Professor of Nutrition and Epidemiology, Harvard T.H. Chan School of Public Health
Co-director of the Program in Obesity Epidemiology and Prevention at Harvard
Member of U.S. National Academy of Medicine

Dr. Hu received his MD from Tongji Medical College in China and a PhD in Epidemiology from University of Illinois at Chicago. His research is mainly focused on nutritional and lifestyle epidemiology and prevention of obesity, diabetes, cardiovascular disease as well as gene-environment interactions. He has published >800 original papers and reviews (H-index 188) and a textbook on Obesity Epidemiology (Oxford University Press 2008). Dr. Hu is the recipient of the Kelly West Award for Outstanding Achievement in Epidemiology by American Diabetes Association in 2010. He has served on the Institute of Medicine (IOM) Committee on Preventing the Global Epidemic of Cardiovascular Disease, the AHA/ACC Obesity Guideline Expert Panel, and the 2015 Dietary Guidelines Advisory Committee, USDA/HHS. He currently serves on the editorial board of *Lancet Diabetes & Endocrinology*, *Diabetes Care*, and *Clinical Chemistry*. Dr. Hu was elected to the U.S. National Academy of Medicine in 2015.

Yuwen Liu
Founder of Bohe Angel Fund
Former Chairwoman & CEO of BioBAY

Ms. Liu is the Founding Partner of Bohe Angel Fund, jointly invested by Wuxi Apptec, Hengrui, Simcere, TigerMed and BGI, etc. Before she set up this angel fund, she was Executive Director of Suzhou Industrial Park Biotech Development Co. Ltd. (BioBAY) and chairwoman & CEO for 9 years. She was also Investment Committee Member for BioVENTURE and Board Director of Innovent, Admera, Chiral Quest, GenePharma, Reproposing and BrightGene, and Chairwoman of Qiagen (Suzhou) Translational Medicine and Suzhou BioTOP Biotech. She joined the company as EVP in 2005, was instrumental in building BioBAY to be one of the fastest growing biotech clusters serving ~400 biotech startup companies. She started her career as QA Engineer for Capsugel in 1997, then moved up to QC manager, QA/QC manager and BD manager until joined Perrigo as first China Chief Representative in 2003. Yuwen graduated from China Pharmaceutical University with master degree in Pharmaceutics and Master of Management at Fudan University and Norwegian Management School BI, and is a licensed pharmacist.